The previous edition of the consensus guidelines of the International Workshop on Chronic
Lymphocytic Leukemia (iwCLL), published in 2008, has found broad acceptance by …

Cytomegalovirus (CMV) reactivation remains one of the most common and life-threatening
infectious complications following allogeneic hematopoietic stem cell transplantation …

Background Therapies for refractory cytomegalovirus infections (with or without resistance
[R/R]) in transplant recipients are limited by toxicities. Maribavir has multimodal anti …

Despite advances in preventive strategies, cytomegalovirus (CMV) infection remains a major
complication in solid organ and hematopoietic cell transplant recipients. CMV infection may …

This review focuses on recent advances in the field of cytomegalovirus (CMV). The 2 main
strategies for CMV prevention are prophylaxis and preemptive therapy. Prophylaxis …

Cytomegalovirus (CMV) infection after hematopoietic stem cell transplantation (HSCT) is
one of the critical infectious complications related to host immune recovery. The spectrum of …

Human cytomegalovirus (HCMV) reactivation is a major infectious cause of morbidity and
mortality after allogeneic hematopoietic stem cell transplantation (HSCT). HCMV is a …

Hosts with compromised or naive immune systems, such as individuals living with HIV/AIDS,
transplant recipients, and fetuses, are at the highest risk for complications from …

Background Cytomegalovirus (CMV) reactivation is one of the most common infectious
complications after allogeneic hematopoietic cell transplant (HCT) and may result in …

Therapies reconstituting autologous antiviral immunocompetence may represent an
important prophylaxis and treatment for immunosuppressed individuals. Following …